Merck Seeks Emergency Use Authorization for Antiviral COVID-19 Treatment Molnupiravir.<br />Merck and Ridgeback Biotherapeutics <br />said Monday that it is seeking emergency use authorization for its antiviral treatment, molnupiravir.<br />from the U.S. Food and Drug Administration.<br />At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%, Merck, via statement.<br />During a White House COVID-19 <br />briefing last week, Dr. Anthony Fauci said <br />the trial results are “very encouraging.”.<br />It is very important that <br />this now must go through <br />the usual process of <br />careful examination.., Dr. Anthony Fauci, via briefing.<br />... of the data by the Food and Drug Administration <br />both for effectiveness, <br />but also for safety. , Dr. Anthony Fauci, via briefing.<br />If authorization is granted, it will <br />be the first oral antiviral treatment <br />to fight the coronavirus.<br />The drug comes in capsule form.<br />The company said that it will <br />provide tiered pricing so that the drug <br />will be accessible around the world.<br />Merck also said it will work with <br />generic drug manufacturers so <br />that low- and middle-income <br />countries will also have access.
